Prostate cancer is one of the leading causes of cancer-related death in men. Despite significant advances in prostate cancer diagnosis and management, the molecular events involved in the transformation of normal prostate cells into cancer cells have not been fully understood. It is generally accepted that prostate cancer derives from the basal compartment while expressing luminal markers. We investigated whether downregulation of the basal protein B-cell translocation gene 2 (BTG2) is implicated in prostate cancer transformation and progression. Here we show that BTG2 loss can shift normal prostate basal cells towards luminal markers expression, a phenotype also accompanied by the appearance of epithelial-mesenchymal transition (EMT) traits. We also show that the overexpression of microRNA (miR)-21 suppresses BTG2 levels and promotes the acquisition of luminal markers and EMT in prostate cells. Furthermore, by using an innovative lentiviral vector able to compete with endogenous mRNA through the overexpression of the 3 0 -untranslated region of BTG2, we demonstrate that in prostate tumor cells, the levels of luminal and EMT markers can be reduced by derepression of BTG2 from microRNA-mediated control. Finally, we show that the loss of BTG2 expression confers to non-tumorigenic prostate cells ability to grow in an orthotopic murine model, thus demonstrating the central role of BTG2 downregulaton in prostate cancer biology.
INTRODUCTION
Although much progress has been made in prostate cancer diagnosis and management over the last few decades, prostate tumors still represent one of the leading causes of cancer-related death in men. 1 The malignant transformation can occur through progressive acquisition of genetic and epigenetic lesions, coupled with increasing microenvironmental stimuli. However, early molecular events underlying the oncogenic process in the prostate remain largely unknown. Prostate acini are composed of a luminal compartment of differentiated cells surrounded by an undifferentiated layer of basal cells. A transit-amplifying population composed of intermediate progenitors retaining both basal and luminal markers mirrors a continuum in the differentiation program. 2 Basal cells have been traditionally considered the cells of origin of prostate cancer. 3 However, how cancer cells may both express luminal cell markers 4, 5 and have functional properties of basal cells, such as unlimited self-renewal capacity 6 and activation of survival mechanisms, continues to remain controversial. 7 Unlike prostate cancer cells, the basal layer of normal prostate acini expresses considerable levels of DNp63a, an isoform of p63 involved in stemness maintenance and differentiation control during prostate organogenesis. 8, 9 In addition, DNp63 loss has been associated with enhanced motility and epithelial-mesenchymal transition (EMT), 10 ,11 a trans-differentiation process through which cancer cells lose their epithelial characteristics, whereas acquiring a mesenchymallike phenotype associated with the acquisition of migratory and invasive traits. 12 The basal cell compartment is also a major site of expression of the B-cell translocation gene 2 (BTG2). 13 BTG2 is a pan-cell cycle modulator and a major effector of p53-induced proliferation arrest that exerts its biological activity by inhibiting the expression of cyclin D1 and the phosphorylation of Rb. [14] [15] [16] In addition, knockdown of BTG2 revealed its cooperation with the RAS oncogene in inducing cell transformation. 17 The tumorsuppressive role of BTG2 is supported by its downregulation in several tumors, including clear cell renal carcinoma, 18 breast cancer 19 and prostate adenocarcinoma. 20 It is well established that post-transcriptional modifications modulate gene expression. MicroRNAs (miRs) are small, noncoding, single-stranded RNAs that suppress mRNA translation of specific target genes. 21 A compelling body of evidence indicates that miRs control nearly all basic cell functions 22 and that their deregulation is deeply implicated in tumor development and progression. [23] [24] [25] miR-21 upregulation occurs in many cancers including prostate tumors. [26] [27] [28] It has also been correlated with tumor aggressiveness, androgen-dependent and independent prostate cancer growth, and metastatic spread. 29 , 30 Here we demonstrate a novel role of miR-21 in driving prostate cells toward acquiring a malignant phenotype via the downregulation of BTG2.
RESULTS

BTG2 is downregulated in prostate tumors and cancer cell lines
We evaluated, by immunohistochemistry, the expression of BTG2 in five specimens of prostate tumors and five normal prostate tissues. The analysis confirmed that BTG2 expression is confined to the basal cell layer of normal tissues (60-70% of cells), with a prevalent staining of both nuclei and cytoplasm, and a minority of either nuclear or cytoplasmatic localization. BTG2 staining was negative in luminal cells of both normal prostate acini and tumor tissues (Figure 1a) . However, in some cases, BTG2 was detected in luminal cells of acini dispersed in tumor areas, as highlighted by co-staining of BTG2 and cytokeratins 8 and 18 (CK8-18; Figure 1b) . To further corroborate the downregulation of BTG2 in prostate tumors, we evaluated its expression in primary cells isolated from five prostate tumors. Flow cytometry analysis confirmed BTG2 downregulation in cancer cells as compared with normal primary cells (Supplementary Figure S1A) . We validated the specificity of our BTG2 staining by BTG2 immunoprecipitation and detection with a non-commercial anti-BTG2 antibody 31 (Supplementary Figure S1B) . To investigate the consequences of BTG2 downregulation in prostate cancer, we evaluated BTG2 levels in our experimental model, comparing its expression in three established prostate cell lines representing different phases of prostate tumorigenesis: (i) immortalized non-tumorigenic RWPE-1 cells, (ii) early tumoral RWPE-2 cells and (iii) metastasis-derived PC3 cells. Cytofluorimetric analysis revealed a progressive reduction of BTG2 expression in this series of cell lines (Figure 1c) . Notably, in RWPE-1 cells, BTG2 protein is strongly expressed in the nuclei of small round cells, while residing in the cytoplasm of larger cells (Figure 1d ). Given the role that BTG2 has as a transcriptional cofactor, nuclear localization suggests that its transcriptional function can be exploited only in a subpopulation of cells. 32 RWPE-1 is a heterogeneous cell line composed of a progenitor subpopulation, an intermediate population co-expressing basal and luminal cytokeratins, and a more differentiated cell fraction. 33, 34 p63 protein is expressed by most of the population, with higher levels in the smaller, undifferentiated cells, whereas CK8-18 are mainly expressed by larger, differentiated cells ( Figure 1e ). As prostate tumor cells are largely characterized by the expression of luminal markers while progenitor cells have a basal phenotype, RWPE-1 cells represent a valuable model for studying phenotype modification during neoplastic transformation.
BTG2 knockdown leads acquisition of a luminal phenotype and EMT The prostate basal cell-restricted expression of BTG2, its absence in the nuclei of more differentiated cells and its loss in prostate tumors led us to speculate an involvement of BTG2 in maintaining the basal compartment. To test this hypothesis, we performed transient RNA interference of BTG2 in RWPE-1 cells (Figure 2a and Supplementary Figure S2A ). As compared with control cells, RWPE-1 transfected with small interefering RNA (siRNA) BTG2 showed a change in cell morphology, with an increase of larger spindle shape cells, as revealed by phalloidin staining of the cytoskeleton (Figure 2b ). Evaluation of marker expression demonstrated an increase of the luminal proteins CK8-18 and androgen receptor (AR), with a parallel decrease in the expression of the typical basal marker p63 (Figure 2c ). Given the importance of p63 as a transcriptional regulator, we investigated whether p63 reduction might result in similar features and potentially mediate the effects of BTG2 downregulation. We therefore performed RNA interference of p63 in RWPE-1 cells, observing a strong upregulation of luminal markers CK8-18 and AR (Supplementary Figure  S2B) . Therefore, BTG2 and p63 interference both result in the acquisition of a luminal phenotype. As BTG2 has been reported to suppress RAS activity, 17, 35 we investigated whether the reduction of p63 in BTG2-interfered cells could be because of the activation of the ERK signaling. The concurrent interference of KRAS was indeed able to rescue p63 levels (Supplementary Figure S2C) . p63 loss has also been associated with EMT, 10 the process through which epithelial cells acquire a more elongated, motile phenotype associated with the expression of mesenchymal markers like vimentin and fibronectin, and the loss of the epithelial adhesion molecule E-Cadherin. We verified this mechanism in prostate cells by evaluating the levels of vimentin upon interference and overexpression of p63. In RWPE-1 cells, RNA interference against all p63 and DNp63 isoforms resulted in upregulation of vimentin (Supplementary Figure S2D) . Conversely, in RWPE-2 cells, which express higher levels of vimentin, the overexpression of DNp63 reduced this mesenchymal marker, whereas a TAp63-carrying plasmid did not (Supplementary Figure S2D) . This suggests that only DNp63 isoforms can control the expression of vimentin. We therefore evaluated whether BTG2 interference might also result in EMT. Flow cytometry and immunofluorescence analyses showed mesenchymal markers induction in BTG2-interfered cells (Figure 2d and Supplementary Figure S2E) . Similarly, E-Cadherin staining underlined a partial disorganization of epithelial junctions, and flow cytometry confirmed a 30% reduction of E-Cadherin-positive cells (Figure 2e ). This phenotype correlated with an increase in motility, as shown by migration assay in Boyden chambers (Figure 2f ). miR-21 overexpression reproduces the effects of BTG2 knockdown We next explored the possible mechanisms responsible for BTG2 downregulation in prostate cancer. A posttranscriptional control of BTG2 in prostate cancer was hypothesized. 20 The established oncogene miR-21 36, 37 is overexpressed in many cancers, including prostate cancer. 26, 27, 30 A direct regulation of BTG2 protein expression by miR-21 has been recently demonstrated in laryngeal carcinoma. 38 First, we confirmed the direct binding of BTG2 3 0 -untranslated region (UTR) by miR-21 with luciferase assay in prostate and non-prostate cells (Figure 3a and Supplementary Figure S3A ), whereas p63 did not result to be a miR-21 target (Supplementary Figure S3A and Supplementary information). Afterwards, we transduced RWPE-1 cells with the TWEEN (TW) lentiviral vector, 39 engineered to drive the constitutive expression of miR-21. As compared with TW-infected cells, miR-21 overexpressing RWPE-1 cells downregulated BTG2 protein expression by more than 50% (Figure 3b ). We then analyzed the phenotype of RWPE-1 miR-21 cells and observed comparable features with BTG2-interfered cells, such as decrease of p63, induction of CK8-18 and AR (Figure 3c ), as well as upregulation of vimentin and fibronectin ( Figure 3d ) and reduction of E-Cadherinpositive cells (Figure 3e ). In miR-21-overexpressing cells, the transfection of DNp63 could reduce CK8-18 and vimentin levels, confirming the participation of this molecule in the observed phenotype (Supplementary Figure S3B) . Thus, the ectopic expression of miR-21 was able to recapitulate the mesenchymallike changes induced by the knockdown of BTG2. As the wellestablished miR-21 target PDCD4 40 has been shown to inhibit the mesenchymal transition in colon cancer cells, 41 we confirmed PDCD4 as miR-21 target and investigated whether its knockdown by short hairpin RNA (shRNA) could reproduce EMT traits. Consistently, androgen-independent PC3 and DU145 cells have almost undetectable BTG2 protein, contrary to androgen-dependent LNCaP and 22RV1, which retain some expression ( Figure 3f) . Thus, the levels of BTG2 in androgen-dependent cancer cells are higher than in androgen-independent cell lines, but still lower than in normal cells, indicating that a progressive loss of BTG2 may correlate with tumor progression. We supposed that, in androgen-dependent prostate cancer cells, basal levels of BTG2 might represent an anti-oncogenic mechanism to prevent progression to advanced stages. As LNCaP and 22RV1 cells are both p53-proficient, while PC3 and DU145 are p53-deleted or -mutated, respectively, we reasoned that in androgen-dependent Figure S5A ). However, we cannot exclude that other mechanisms might intervene in the complex network governing prostate cancer progression. 42 We then analyzed miR-21 in 27 samples of primary prostate tumor cells and observed that miR-21 was expressed at high or moderate level in about half of the patients (Supplementary Figure S5B) . By setting an arbitrary cutoff level of miR-21 at 2, Gleason grade 47 and pT3N0M0 were observed in 5/11 cases with miR- 21 42 Figure S5C) . Interestingly, also a low degree of miR-21 overexpression increased levels of CK8-18 and vimentin, with a number of cells fluctuating in a state in which they are simultaneously expressed (Supplementary Figure S5C) . To clarify this dual role of miR-21, RWPE-1 cells were transfected with miR-21 precursor oligo, and the expression of CK8-18 and vimentin was analyzed after 24 and 96 h. Transfection resulted in massive miR-21 overexpression (approximately 500-fold). A marked CK8-18 upregulation was observed at 24 h, whereas vimentin overexpression was detected only at 96 h (Supplementary Figure S5D) . This suggests that miR-21 shot first induces luminal markers expression, whereas a prolonged upregulation enables aberrant expression of both CK8-18 and vimentin. EMT is largely considered a prelude to the spread of metastases. Notably, prostate lymphonodal metastases express CK8-18 (Supplementary Figure S5E) , indicating that the induction of both features may be necessary for prostate cancer progression. In an effort to clarify whether BTG2/miR-21 axis has a role in physiological differentiation, we tried to differentiate in vitro RWPE-1 cells by exposure to dihydrotestosterone for 1 week. We observed a partial differentiation of RWPE-1, as documented by a decrease of p63 and an increase of CK8-18 (Supplementary Figure  S6A) . This process was accompanied by a reduction of BTG2 mRNA and by a decrease/delocalization of BTG2 protein ( Supplementary  Figures S6B and C) . However, miR-21 levels were not increased but rather decreased in the course of the differentiation process (Supplementary Figure S6C) . This suggests that physiological differentiation is independent of miR-21 increase, and that putative tumor-suppressor mechanisms might rather reduce miR-21 levels to avoid cell transformation. Thus, miR-21-mediated regulation of BTG2 appears relevant only for tumor transformation and cancer progression.
Derepression of BTG2 mRNA can reduce luminal phenotype and EMT We then aimed at investigating the consequences of BTG2 restoration in RWPE-2 cells. Consistently with miR-21 increase, we observed an accumulation of the luminal markers CK8-18 and AR in these early-tumoral cells (Supplementary Figure S7A) . The transduction of these cells with a lentiviral construct carrying only BTG2 coding sequence (TW BTG2) resulted in dramatic growth arrest (Figure 4a ). Similar effects were observed upon BTG2 overexpression in PC3 cells (Supplementary Figure S7B) . In an effort to confirm the role of BTG2 in basal-luminal shift and EMT in a tumoral model, we devised a system to obtain a selective and more physiological BTG2 restoration by interfering with miRmediated control of BTG2 levels. We produced a lentiviral vector, called TW-3 0 -UTR-BTG2 (UTR-BTG2), in which a region of the 3 0 -UTR of BTG2, including miR-21 binding sites, is inserted in the 3 0 -UTR of the enhanced green fluorescent protein (EGFP). (Figure 4b ). This vector produces a stable EGFP transgene with a chimera 3 0 -UTR able to bind excess of miR-21 and release endogenous BTG2 from posttranscriptional control. The efficacy of this system was demonstrated by an increase of BTG2 levels in RWPE-2 cells infected with UTR-BTG2, as compared with empty vector-transduced cells (Figure 4c ). This increase was sufficient to significantly impact cell growth (Figure 4d ), but to a lower extent than the overexpression of BTG2 coding sequence. Consistently with reduced proliferation, RWPE-2 UTR-BTG2 cells showed a marked reduction of Cyclin D1 and pRb (Figure 4e and Supplementary Figure S7C) . Importantly, other established miR-21 targets, Sprouty-2 43 and PTEN, 44 were not affected in the RWPE-2 UTR-BTG2 cells (Figure 4f and Supplementary Figure S7D) , suggesting a selective modulation of the targeting of miR-21 on the 3 0 -UTR of BTG2. It is worthy to note that, the restoration of BTG2 levels could shift the phenotype of RWPE-2 cells, as shown by upregulation of p63, downregulation of CK8-18, vimentin and fibronectin (Figures 4f and g and Supplementary Figures S7D, E and F). RWPE-2 UTR-BTG2 cells showed an increase of nuclear localization of BTG2 and a parallel mild p63 expression (Supplementary Figure S8A) . Similar effects were obtained in PC3 cells transduced with UTR-BTG2 vector (Supplementary Figure S8B) . To confirm this latter result, we verified that, although at low levels, BTG2 and p63 mRNA could be detected in PC3 cells and were also modified by the UTR-BTG2 overexpression (Supplementary Figure S8C) . The UTR-BTG2 transduction in RWPE-1 miR-21 cells was able to reduce EMT traits (Supplementary Figure S8D) . As the restoration of BTG2 levels by the UTR-BTG2 overexpression could theoretically be due to depleting other microRNAs capable of binding the 3 0 -UTR of BTG2, we verified that similar effects could be reproduced by miR-21 knockdown in RWPE-2 cells by engineering the lentiviral vector TW 3 0 -UTR Decoy 39 in order to selectively sequester miR-21 (Decoy 21) (Supplementary Figure S8E) .
BTG2 knockdown allows orthotopic engraftment of normal prostate cells
We next investigated the consequences of BTG2 loss on prostate tumorigenesis. AR overexpression has been shown to enable tumor formation by previously immortalized normal prostate epithelial cells in an orthotopic mouse model. 45 Although BTG2 interference did not result in any significant proliferative advantage in vitro (data not shown), we hypothesized that its ability to upregulate AR and induce a luminal phenotype may be relevant for in vivo engraftment and growth. Therefore, we stably knocked down BTG2 in RWPE-1 by inserting shRNAs against BTG2 in pLox lentiviral vector (shRNA BTG2), 46 which includes a cassette for EGFP reporter expression. Levels of BTG2 mRNA were reduced by 50% in RWPE-1 shRNA BTG2 cells (data not shown). Control and BTG2-interfered RWPE-1 cells were then inoculated in the left anterior prostate of 10 immunodeficient mice for each group, and dihydrotestosterone pellets were subcutaneously implanted to ensure optimal hormonal support. Mice were killed 7 weeks after surgery, and prostates observed at the stereomicroscope to evaluate the engraftment of human prostate cells on the basis of EGFP signal. The absence or presence of an EGFP signal was then used to calculate the rate of engraftment. Significantly, prostates inoculated with control RWPE-1 pLox cells did not show any fluorescent signal in 7/10 cases, whereas in 3/10 prostates, a weak EGFP positivity was detected. Conversely, only 2/10 prostates inoculated with RWPE-1 shRNA BTG2 were negative for EGFP, whereas in 8/10 cases, EGFP signal revealed a striking capacity of these cells to grow in an orthotopic site, as demonstrated by a strong EGFP signal in 6/10 prostate and a weaker positivity in 2/10 ( Figure 5a ). Consistently, hematoxylin and eosin staining of xenografts sections revealed a massive presence of RWPE-1 shRNA BTG2 cells invading the murine prostate (Figure 5b) . Thus, BTG2 loss may be per se an oncogenic mechanism. 
DISCUSSION
In this study, we demonstrated that BTG2 targeting by miR-21 promotes the shift of prostatic basal cells towards the luminal phenotype coupled with the appearance of EMT features and increased tumorigenic activity. It is generally accepted that prostate cancer cells derive from the basal compartment, but express luminal markers. 47 Given that the tumor suppressor BTG2 is differently expressed within the epithelial populations of prostate cells (basal versus luminal) and lost in prostate cancer, we investigated whether BTG2 downregulation could be implicated in cell transformation and cancer progression. To this aim, we employed a strategy of BTG2 interference in RWPE-1, a normal non-tumorigenic cell line composed by two subpopulations that differ in size and differentiation status. 48 We showed that BTG2 downregulation can shift the balance between these subpopulations, leading to the accumulation of large ARpositive cells expressing high CK8-18 and low p63 levels. In a widely accepted model of prostate development and neoplastic transformation, a small stem cell population located in the basal cell layer gives rise to all epithelial cell lineages encountered in the normal, hyperplastic and neoplastic tissues. 3 The differentiating process can be induced by circulating androgens, largely depending on the presence of androgen-responsive target cells. 49 Accordingly, the abnormal growth of the secretory epithelium in benign prostate hyperplasia may be related to an increase in the total number of androgen-responsive cells. Berger et al. 45 demonstrated that the overexpression of AR was sufficient to convert immortalized prostate epithelial cells into differentiated secretory cells that recapitulated the phenotype associated with human prostate cancer and were able to grow in an orthotopic murine model. Similar results were obtained in our model of BTG2 knockdown in RWPE-1 cells, whose growth occurred upon orthotopic, but not subcutaneous injection (data not shown). Therefore, dysregulation of the miR-21/BTG2 axis may not be sufficient to make normal cells tumorigenic without the contribution of a suitable microenvironment. We demonstrated that in prostate cells, the overexpression of the established oncogene miR-21 can suppress BTG2 expression and reproduce the effects observed upon BTG2 interference. Interestingly, the overexpression of miR-21 in AR-positive LNCaP and 22RV1 cells further increases the amount of receptor, possibly increasing sensitivity to lower levels of androgens. This finding is in line with previous observations showing that the inhibition of miR-21 can reduce androgen-induced prostate cancer cell proliferation, and that elevated expression of miR-21 in prostate cancer cells enhances tumor growth in vivo and allows androgen-dependent tumors to overcome castration-mediated growth arrest. 30 Furthermore, serum miR-21 levels have been reported to correlate with those of the prostate-specific antigen in patients with androgen-dependent and -independent prostate cancer. 27 In addition, a positive feedback loop can be designed by joining our observations with the reported transactivation of miR-21 promoter by AR. 30 Therefore, we envisage that miR-21 induction may sustain AR signaling, participating in molecular mechanisms involved in resisting endocrine therapy. In light of the above, low or moderate levels of miR-21 detected in some cell lines, as well as in a subgroup of primary prostate tumor cells, may represent a strategy to prevent progression to castration resistance. It is conceivable that low levels of miR-21 and an induction of BTG2, a p53 responsive gene, might represent a feedback mechanism able to brake proliferation in response to cellular growth signals. Consistently, functional studies indicated that ectopic expression of BTG2 caused a significant inhibition of the AR-mediated transcriptional activity, an attenuation of prostate-specific antigen levels and a decreased growth of prostate cancer cells. 50 This is also consistent with our observation showing luminal expression of BTG2 in acini dispersed in tumor areas, having been previously reported overexpression of BTG2 in the hyperproliferative lesions simple atrophy, post-atrophic hyperplasia and proliferative inflammatory atrophy. 20 Interestingly, the luminal phenotype induced by BTG2 knockdown and miR-21 overexpression was accompanied by the acquisition of mesenchymal-like traits. EMT is a trans-differentiation process that illustrates the plasticity of cancer cells and is thought to mark a key step towards the spread of metastases. 12 Interestingly, several reports emphasize that circulating tumor cells coexpress epithelial and mesenchymal markers. 51 In our model, this phenotype may be explained by the influence of BTG2 on the levels of the tumor suppressor DNp63. However, given the inhibitory effect of BTG2 on RAS activity, 35 we cannot exclude that an enhanced ERK signaling due to BTG2 loss may be involved in inducing this phenotype. Interestingly, the effects observed upon BTG2 knockdown in non-tumorigenic RWPE-1 cells could be reverted in early-tumoral RWPE-2 cells upon derepression of BTG2 mRNA. A vector to overexpress the 3 0 -UTR of a given gene to compete with endogenous mRNA for microRNA binding is an original tool to finely modulate gene expression. This can be especially useful in the study of tumor suppressor genes like BTG2. In these cases, a careful dosage of gene expression may be necessary to unveil novel functions normally masked by the dramatic effects on cell growth and viability due to the artificial overexpression of the coding sequence. . Primary antibodies were diluted at the previously indicated concentrations in phosphate-buffered saline 3% bovine serum albumin, 0.05% Triton X-100 and incubated overnight at 4 1C. After extensive washing, coverslips were incubated for 45 min at room temperature with the appropriate secondary antibodies diluted 1:2000. For vimentinfibronectin or vimentin-CK8-18 co-staining, Alexa Fluor 555-and 647-conjugated antibodies were used. For BTG2-p63 co-staining, 647-conjugated donkey anti goat and TRITC-conjugated rabbit anti mouse antibodies were used. After extensive washing, the nuclei were stained with DAPI (4 0 , 6 0 -diamidino-2-phenylindole) for 20 min. Cytoskeletal actin was stained with Alexa Fluor 488-conjugated Phalloidin (200U/staining; A12379; Invitrogen). Coverslips were mounted on microscope slides and sealed. Primary antibody-free controls were produced. Images were collected on a fluorescence confocal microscope (Olympus FV1000; Olympus, Tokyo, Japan). For the analysis of prostate specimens, samples obtained from radical prostatectomy were snap-frozen in optimal cutting temperature compound (OCT) and stored at À 80 1C. Cryostatic sections were obtained with a cryomicrotome (Kriostat 1720 MGW; Leitz, Melville, NY, USA).
MATERIALS AND METHODS
Flow cytometry and immunofluorescence
Transfection RWPE-1 cells were transfected with 30 nM of either negative control or premiR-21 (Ambion/Applied Biosystems, Foster City, California, CA, USA), Hs_BTG2_6, Hs_KRAS_3 plus Hs_KRAS_8 FlexiTube siRNAs (Qiagen, Hilden, Germany) and p63 siRNAs, using the Hiperfect transfection reagent (Qiagen). RWPE-2 or RWPE-1 miR-21 cells were transfected with expression constructs pCS2, pCS2 DNp63 and pCS2 TAp63 using Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. p63 siRNAs and expression constructs are referenced in Adorno et al. 11 Unless differently indicated, cells were collected 72 h after transfection for further analysis.
Generation of lentiviral vectors and gene transfer
For TWmiR-21 generation, miR-21 precursor DNA was PCR amplified from human genomic DNA with the following primers: forward 5 0 -cacactctgtcg tatctg-3 0 ; reverse 5 0 -gactatccccatttctcc-3 0 . The 618 bp fragment was subcloned into the lentiviral vector TW under the control of the cytomegalovirus promoter. For BTG2 overexpression, the 476 bp of BTG2 coding sequence were cloned in the TW vector under the control of the cytomegalovirus promoter. Primers to amplify the coding sequence were: forward 5 0 -acatgagccacgggaag-3 0 ; reverse 5 0 -gaagggcctagctggaga-3 0 . For TW-3 0 -UTR-BTG2 generation, an 808 bp fragment of BTG2 3 0 -UTR including miR-21 binding site was PCR amplified from human genomic DNA with the following primers: forward 5 0 -ggaaaggttgctgtctgtctc-3 0 ; reverse 5 0 -ggtgta catttgtccataagctg-3 0 . TW 3 0 -UTR Decoy 21 was generated by synthesizing two antisense sequences of miR-21 separated by a stem-loop spacer. The fragments were subcloned in the EGFP 3 0 -UTR of the TW3 0 vector described in Bonci et al., 39 endowed with a puromycin-resistance cassette. For the pLox shRNA BTG2 and PDCD4 generation, the following sequences were chosen for shRNA design according to the instructions reported in Rubinson et al.
46
: for BTG2, 5 0 -tcaaccacaagatggaccc-3 0 ; 5 0 -ggagaaaagtg gaaagcta-3 0 ; 5 0 -gaaacaaagctgtgaatca-3 0 ; for PDCD4 5 0 -atcctgataacttaagt-3 0 ; 5 0 -aactgtgtttatgaaac-3 0 . About 50 nucleotide long stem-loop sense and antisense oligonucleotides were synthesized and 60 pmol of each oligo were in vitro annealed by incubating the reaction in the annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH pH 7.4, 2 mM magnesium acetate) for 4 min at 95 1C, 10 min at 70 1C and by slowly decreasing the temperature down to 4 1C (1 1C/min). Lentiviral particles were produced as previously described. 52 Cells were transduced with 1 Â 10 6 viral transducing units per ml, unless differently indicated. For BTG2 and PDCD4 stable interference, viruses encoding different shRNA sequences were mixed in equal volumes. EGFP was used as a reporter and EGFP bright cells were sorted with BD FACSAria (Becton, Dickinson and Company). The selection of cells transduced with TW 3 0 -UTR and TW 3 0 -UTR-BTG2 was performed by applying 1 mg/ml puromycin for 48 h. For p53 interference, constructs described in Cecchinelli et al. 53 were used.
Statistical analysis
Plotted data are presented as the mean þ s. 
